在高海拔地区和平原地区的患有超脂血症的患者中,阿托瓦斯塔丁的人口药理动力学
Yu Li1,2, Qin Huang1, Xianghai Zeng1,2
1Department of Pharmacy, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, China.
Journal of clinical pharmacology
|October 21, 2023
概括
高海拔低氧会改变阿托瓦斯塔丁 (ATV) 在高脂血症患者中的药理动力学. 高原居民的ATV度较高,这表明在高海拔地区可能需要减少剂量.
科学领域:
- 药理动力学 药理动力学
- 高度医学 高度医学
- 心血管药理学心血管药理学
背景情况:
- 已知药物药理动力学 (PK) 被高海拔低氧影响.
- 阿托瓦斯塔丁 (ATV) 是一种常见的超脂血症治疗方法.
研究的目的:
- 在高脂血症患者中描述阿托瓦斯塔丁 (ATV) 的人口PK.
- 为了确定影响ATV PK变异性的患者特征.
- 为了研究高海拔低氧对ATV血度的影响.
主要方法:
- 使用非线性混合效应建模开发了一种种群的药理动力学模型.
- 从高原地区的40名高脂血症患者和平原地区的40名患者分析了160个血度.
- 一个具有第一阶段淘汰的单间模型被用来描述ATV PK.
主要成果:
- 关键的ATV PK参数包括清除量 (174.22 L/h) 和分布量 (1119.62 L).
- 年龄和面积是清除和分布量的重要共变量.
- 与平原地区相比,平原地区的ATV稳定状态峰值度在高原地区更高.
结论:
- 高海拔低氧显著影响阿托瓦斯塔丁 (ATV) 药理学在高脂血症患者.
- 患者的年龄和居住区域是影响ATV配置的重要因素.
- 建议在居住在高海拔地区的高脂血症患者中降低阿托瓦斯塔丁剂量的潜在需要.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
676
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
676
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
42
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
42
Time Course of Drug Effect
2.1K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.1K
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
167
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
167
Drug Distribution: Plasma Protein Binding
5.7K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.7K


